Health Care Resource Utilization (HCRU) with Asciminib and Bosutinib among Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs): Results from the Multicenter, Open-Label Phase 3 ASCEMBL Trial

被引：0

作者：

Smith, B. Douglas ^{[1
]}

Cortes, Jorge E. ^{[2
]}

Rea, Delphine ^{[3
]}

Mauro, Michael J. ^{[4
]}

Patwardhan, Pallavi ^{[5
]}

Maegawa, Rodrigo ^{[5
]}

Zacker, Christopher ^{[5
]}

Corbin, Regina ^{[5
]}

Keeping, Sam ^{[6
]}

Sasaki, Koji ^{[7
]}

机构：

[1] Johns Hopkins Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

[2] Augusta Univ, Georgia Canc Ctr, Augusta, GA USA

[3] Hop St Louis, AP HP, Dept Hematol, Paris, France

[4] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[5] Novartis Pharmaceut, E Hanover, NJ USA

[6] PRECISIONheor, Vancouver, BC, Canada

[7] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

来源：

关键词：

CML; chronic myeloid leukemia; health care resource use; asciminib; bosutinib; tyrosine kinase inhibitor;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CML-353

引用

页码：S334 / S334

页数：1